A federal government advisory body has refused to recommend listing a new Alzheimer’s drug, leaving patients to bear ...

While the United States remains a major market due to advanced research and telemedicine adoption (CAGR: 4.5%), Asia-Pacific ...

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

A federal government advisory body has refused to recommend listing a new Alzheimer’s drug, leaving patients to bear staggering costs to use it. Kisunla (donanemab), a disease-modifying therapy ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug.

Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

By Kami McDonald, Student Pharmacist and Karen L. Kier, Pharmacist ONU Healthwise Pharmacy ...

Indianapolis: Eli Lilly and Company has announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective ...

The spot, which prominently utilizes a cover of “Here Comes the Sun” by The Beatles, manages to balance a message of hope with the somber nature of Alzheimer’s.

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...